Relmada Therapeutics (RLMD) Liabilities and Shareholders Equity (2012 - 2026)
Relmada Therapeutics (RLMD) recorded Liabilities and Shareholders Equity of $219.06 million in Q2 2026, up 937.4% from $21.12 million a year earlier but down 6.9% from the prior quarter.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Liabilities and Shareholders Equity (2012 - 2026) Analysis & Trends
At the end of FY2025, Relmada Therapeutics reported Liabilities and Shareholders Equity of $94 million, up 105.2% from FY2024.
- Annual Liabilities and Shareholders Equity has a five-year compound annual growth rate of -4.5% (FY2020 to FY2025).
- Across earlier years, Liabilities and Shareholders Equity came in at $45.82 million in FY2024 (-53.0%), $97.55 million in FY2023 (-36.2%), $152.91 million in FY2022 (-31.5%) and $223.33 million in FY2021 (+89.0%).
- Quarterly Liabilities and Shareholders Equity has ranged from $14.88 million in Q3 2025 to $235.36 million in Q1 2026 over the past five years.
- On a year-over-year basis, Liabilities and Shareholders Equity has increased for three consecutive quarters, with growth averaging 185.0% over the last eight quarters.
- Peak year-over-year performance for Liabilities and Shareholders Equity in the last five years was growth of 937.4% in Q2 2026, against a decline of 73.3% in Q3 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $235.36 million (Q1 2026), $94 million (Q4 2025) and $14.88 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Relmada Therapeutics | 402.15 Mn | 402.15 Mn | - | 219.06 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 219.06 Mn |
| Mar 31, 2026 | 235.36 Mn |
| Dec 31, 2025 | 94.00 Mn |
| Sep 30, 2025 | 14.88 Mn |
| Jun 30, 2025 | 21.12 Mn |
| Mar 31, 2025 | 27.68 Mn |
| Dec 31, 2024 | 45.82 Mn |
| Sep 30, 2024 | 55.72 Mn |
| Jun 30, 2024 | 71.03 Mn |
| Mar 31, 2024 | 84.41 Mn |
| Dec 31, 2023 | 97.55 Mn |
| Sep 30, 2023 | 109.15 Mn |
| Jun 30, 2023 | 122.04 Mn |
| Mar 31, 2023 | 135.57 Mn |
| Dec 31, 2022 | 152.91 Mn |
| Sep 30, 2022 | 187.12 Mn |
| Jun 30, 2022 | 215.77 Mn |
| Mar 31, 2022 | 225.81 Mn |
| Dec 31, 2021 | 223.33 Mn |
| Sep 30, 2021 | 90.93 Mn |
API Access
Relmada Therapeutics Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=RLMD&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "RLMD", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=RLMD&period=max&api_key=YOUR_API_KEY");
const data = await res.json();